<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Thu, 02 Jul 2026 16:45:20 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[医学] 再発型多発性硬化症と診断されたばかりの患者への古参抗CD20抗体が新参に比肩</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110184&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110184&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 16:45:20 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110184&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 腎癌の手術後のMerck &amp; CoのWelireg込み治療の取り柄を示したPh3試験論文報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110183&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110183&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 16:17:34 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110183&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] BridgeBio社のinfigratinibが小人症の子の1年の身長増加を2cm弱増やした試験報告</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110182&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110182&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 15:11:25 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110182&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BridgeBioが向こう1年間の3つの新薬発売に向けて多ければ10億ドルの投資確保</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110181&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110181&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 14:44:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110181&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 卵巣不全の自己免疫疾患女性の卵子をリツキシマブが成熟できるようにする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110180&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110180&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 13:07:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110180&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Can-FiteがA3AR標的薬の膵癌Ph2a試験のいいとこ取り全生存結果をお披露目</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110179&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110179&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 11:35:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110179&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AlzeCureの臨床試験段階アルツハイマー病薬ACD856をQuantumCell社が手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110178&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110178&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / ライセンス</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 11:12:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110178&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 血液癌を治療するOrca Bio社の細胞詰め合わせTregziを米国FDA承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110177&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110177&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 10:25:34 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110177&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BioCryst社が手前創薬を止めてよそに頼る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110176&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110176&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 組織変更・事業売却/閉鎖</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 10:03:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110176&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph2試験主目標を逃したBKウイルス標的抗体のMemo社をIpsenが買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110175&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110175&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 09:24:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110175&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 透析患者の高リン血症を治療するUnicycive社のリン吸着薬OLCを米国が再び却下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110174&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110174&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 08:05:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110174&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] SLE薬afimetoranのPh2試験結果を今年中に手にするBeeline社が1億ドル強調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110173&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110173&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 02 Jul 2026 07:48:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110173&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 細菌F. prausnitziiが全身性エリテマトーデス（SLE）マウスに有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110172&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110172&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 01 Jul 2026 16:44:10 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110172&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] フィチン酸が炎症性腸疾患マウスの腸のバリア機能を改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110171&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110171&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 01 Jul 2026 16:14:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110171&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Sanofiのポンペ病薬Nexviazymeの生後6か月以下ポンペ病乳児相手のPh3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110170&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110170&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 01 Jul 2026 15:41:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110170&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BeOne社のBTK阻害薬Brukinsaのマントル細胞リンパ腫初治療Ph3試験目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110169&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110169&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 01 Jul 2026 11:24:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110169&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Skyhawk社のハンチントン病薬のPh1/2試験で神経機能検査cUHDRSが好成績</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110168&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110168&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 01 Jul 2026 10:38:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110168&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 手強い患者の集まりの4-5割弱がAbivax社の潰瘍性大腸炎薬obefazimodで寛解</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110167&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110167&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 01 Jul 2026 09:34:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110167&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Zymeworks社がR&amp;D打ち切りのTheravance社を買ってCOPD薬Yupelriを手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110166&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110166&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 17:07:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110166&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ipsenがまず4億5000万ドルを払ってKartos社のPh3試験段階血液癌薬を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110165&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110165&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 15:56:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110165&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rocheの抗IL-6薬Enspryng甲状腺眼症治療の承認申請を米国が優先審査扱いで受理</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110164&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110164&amp;ref=rss</guid>
		<category>開発 / 審査制度 / Priority Review</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 14:34:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110164&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Viridian社の甲状腺眼症（TED）薬Lumvoa静注を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110163&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110163&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 12:20:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110163&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Evommune社のMRGPRX2遮断薬EVO756の蕁麻疹P2b試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110162&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110162&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 11:27:31 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110162&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] AmgenのTavneosの承認の拠り所のPh3試験ADVOCATE報告をNEJMが取り下げ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110161&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110161&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 09:46:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110161&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Modernaが来年末までに臨床試験に進む初の体内仕立てCAR-T・mRNA-6007披露</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110160&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110160&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 新規事業・事業拡大</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 30 Jun 2026 08:50:37 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110160&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Sobiの痛風薬NASP(nanoencapsulated sirolimus plus pegadricase)を米国非承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110159&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110159&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 29 Jun 2026 16:43:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110159&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 寿命を伸ばす遺伝子治療、その名もKlotho(クロトー)を米国Minicircle社が発売する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110158&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110158&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 29 Jun 2026 16:27:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110158&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Epicrispr社の顔面肩甲上腕型筋ジストロフィー薬がPh1/2試験で筋肉量増加を示す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110157&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110157&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 29 Jun 2026 15:35:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110157&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 【増補版】カタコトのアルツハイマー病女性がサイロシビンで会話を取り戻す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110156&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110156&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 29 Jun 2026 14:27:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110156&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] リソソームのカテプシンA阻害でコレステロール値を下げられそう</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110155&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110155&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 29 Jun 2026 07:50:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110155&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ヒトの体を作る多能性細胞を極初期の胚が生み出すのにNANOG遺伝子が必要</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110154&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110154&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 28 Jun 2026 15:53:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110154&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 欧州連合（EU）でのAmgenの補体5a受容体阻害薬Tavneos販売継続が却下された</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110153&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110153&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 販売中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 28 Jun 2026 15:06:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110153&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Replimune社の黒色腫薬RP1の再承認申請を米国FDAが受理</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110152&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110152&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 再承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 28 Jun 2026 07:44:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110152&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 脳卒中患者の力ずくの血栓除去治療後の抗血小板薬チロフィバン投与が有益</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110151&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110151&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 16:51:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110151&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 駆出率低下心不全患者へのグレリン受容体活性化薬AC01投与で大した害見られず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110150&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110150&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 16:22:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110150&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 膀胱と腎臓を一緒に移植することが成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110149&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110149&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 15:48:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110149&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] MRIの磁場で自ずとしぼむバルーンの横隔膜ヘルニア治療が初の臨床試験で有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110148&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110148&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 15:25:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110148&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] オステオポンチン発現が盛んなマクロファージが関節リウマチの組織増殖を誘う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110147&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110147&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 14:56:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110147&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] IgAを作るmRNA投与でノロウイルス感染を食い止めうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110146&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110146&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 13:30:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110146&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 膨大な遺伝配列変化の意義を専門家並みに解する全自動AI手段AI-CURAを開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110145&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110145&amp;ref=rss</guid>
		<category>技術 / 診断 / 全般</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 10:53:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110145&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 6型ネマリン筋症にその変異の住処の遺伝子KBTBD13抑制が有効らしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110144&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110144&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 27 Jun 2026 08:45:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110144&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 提供者からの肝臓の質を表面全体の解析で把握する手段を開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110143&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110143&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 16:48:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110143&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 鉄結合蛋白質トランスフェリンと化学療法の併用で白血病マウス生存が改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110142&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110142&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 16:06:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110142&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] コンゴ民主共和国でのエボラへのMapp/Gileadの抗ウイルス薬の臨床試験が始まる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110141&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110141&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / その他臨床試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 15:42:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110141&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ollin社がRocheのVabysmoに挑むDME/wAMD薬のPh3試験資金3億ドル超調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110140&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110140&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 14:58:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110140&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] GLP-1薬使用患者に嗅覚や味覚の障害が多い</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110139&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110139&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 13:50:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110139&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 自己免疫疾患を治療するT細胞差し向け薬の臨床試験開始資金をOblenio社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110138&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110138&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 11:47:31 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110138&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 大塚製薬のADHD薬centanafadineが不安症でもある患者相手のPh3b試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110137&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110137&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 10:49:45 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110137&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Boehringer IngelheimがImmunaiと組んで癌/自己免疫疾患の新規T細胞標的を探す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110136&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110136&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 10:24:55 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110136&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 独Merck KGaAが試薬、分析機器、診断のBio-Techneをおよそ113億ドルで買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110135&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110135&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 26 Jun 2026 09:51:19 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110135&amp;ref=rss</comments>
	</item>
</channel>
</rss>
